In this episode of The Oncology Insights Podcast, I speak with Ewen Ward, Brand Director at Hanson Wade Group, about the evolution and future direction of antibody drug conjugates in oncology. Ewen explores how ADC innovation is reshaping cancer treatment, from payload design to clinical impact. He also highlights the role of global scientific collaboration through the 16th World ADC London Summit. Listen now on all major platforms!

"Antibody drug conjugates combine targeted antibodies with potent anti-cancer agents, creating therapies designed to improve precision while addressing long-standing toxicity and efficacy challenges."

Meet the guest: Ewen Ward is Brand Director at the Hanson Wade Group, where he leads the development of global scientific conferences focused on antibody-drug conjugates. With a background in biochemistry, his work centers on translating scientific challenges into impactful oncology agendas.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (00:28) Introduction
• (04:36) ADC definition
• (05:53) Toxicity challenges
• (06:51) Payload innovation
• (09:27) Clinical impact
• (11:52) Conference scope
• (31:43) Final Questions

The Oncology Insights Podcast is trusted and supported by innovative companies like:

World ADC London 2026

Beacon - Access to Life Sciences Data - Hanson Wade

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast